18 and older, any sex, with HER2-negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Objective Response Rate (ORR) as Assessed by Independent Radiology Review (IRC)Primary· From the first dose of pamiparib to first documentation of disease progression while participant is alive (Approximately 2 years and 4 months)
ORR is defined as the percentage of participants who achieved a best overall response of confirmed complete response (CR) or partial response (PR), assessed by IRC per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Group
Value
95% CI
TNBC
38.2
25.4 – 52.3
HR(+) /HER2(-) Breast Cancer
61.9
38.4 – 81.9
ORR as Assessed by InvestigatorSecondary· From the first dose of pamiparib to first documentation of disease progression while participant is alive (Approximately 2 years and 10 months)
ORR is defined as the percentage of participants who achieved a best overall response of confirmed complete response (CR) or partial response (PR), assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Group
Value
95% CI
TNBC
36.4
23.8 – 50.4
HR(+) /HER2(-) Breast Cancer
57.1
34.0 – 78.2
Progression-free Survival (PFS) as Assessed by IRC and InvestigatorSecondary· From the first dose of pamiparib to first documentation of disease progression or death (Approximately 2 years and 10 months)
PFS is defined as the time from first dose of pamiparib to the first documented disease progression or death due to any cause, assessed by IRC or the investigator
IRC
Group
Value
95% CI
TNBC
5.49
3.65 – 7.33
HR(+) /HER2(-) Breast Cancer
9.20
7.39 – 11.93
Investigator
Group
Value
95% CI
TNBC
3.78
3.68 – 6.41
HR(+) /HER2(-) Breast Cancer
9.69
5.55 – 12.85
Duration of Response (DOR) as Assessed by IRCSecondary· From first documentation of confirmed CR or PR to first documentation of disease progression or death (Approximately 2 years and 10 months)
DOR is defined as the time from first determination of a confirmed best overall response until the first documentation of progression or death, whichever comes first, assessed by IRC
Group
Value
95% CI
TNBC
6.97
3.94 – NA
HR(+) /HER2(-) Breast Cancer
7.49
5.55 – 14.75
Duration of Response (DOR) as Assessed by the InvestigatorSecondary· From first documentation of confirmed CR or PR to first documentation of disease progression or death (Approximately 2 years and 10 months)
DOR is defined as the time from first determination of a confirmed best overall response until the first documentation of progression or death, whichever comes first, assessed by the investigator
Group
Value
95% CI
TNBC
6.28
4.63 – 11.76
HR(+) /HER2(-) Breast Cancer
11.57
5.95 – 13.90
Confirmed Best Overall Response (BOR) as Assessed by IRC and InvestigatorSecondary· Approximately 2 years and 10 months
BOR is defined as the percentage of participants with best overall response recorded from the start of the treatment until disease progression or recurrence, assessed by IRC or the investigator. BOR included complete response \[CR\], partial response \[PR\], stable disease \[SD\], disease progression and not evaluable \[NE\].
IRC - CR
Group
Value
95% CI
TNBC
5.5
HR(+) /HER2(-) Breast Cancer
4.8
IRC - PR
Group
Value
95% CI
TNBC
32.7
HR(+) /HER2(-) Breast Cancer
57.1
IRC - SD
Group
Value
95% CI
TNBC
34.5
HR(+) /HER2(-) Breast Cancer
28.6
IRC - PD
Group
Value
95% CI
TNBC
27.3
HR(+) /HER2(-) Breast Cancer
9.5
IRC - NE
Group
Value
95% CI
TNBC
0
HR(+) /HER2(-) Breast Cancer
0
Investigator - CR
Group
Value
95% CI
TNBC
3.6
HR(+) /HER2(-) Breast Cancer
0
Investigator - PR
Group
Value
95% CI
TNBC
32.7
HR(+) /HER2(-) Breast Cancer
57.1
Investigator - SD
Group
Value
95% CI
TNBC
36.4
HR(+) /HER2(-) Breast Cancer
23.8
Disease Control Rate (DCR) as Assessed by IRC and InvestigatorSecondary· From the first dose of pamiparib to first documentation of disease progression while participant is alive (Approximately 2 years and 10 months).
DCR is defined as the percentage of participants who achieved a confirmed BOR of CR, PR, or stable disease (SD), assessed by IRC or the investigator
IRC
Group
Value
95% CI
TNBC
72.7
59.0 – 83.9
HR(+) /HER2(-) Breast Cancer
90.5
69.6 – 98.8
Investigator
Group
Value
95% CI
TNBC
72.7
59.0 – 83.9
HR(+) /HER2(-) Breast Cancer
81.0
58.1 – 94.6
Clinical Benefit Rate (CBR) as Assessed by IRC and InvestigatorSecondary· From the first dose of pamiparib to first documentation of disease progression while participant is alive (Approximately 2 years and 10 months)
CBR is defined as percentage of participants with confirmed CR or confirmed PR or a durable SD (SD lasting ≥ 24 weeks), assessed by IRC or the investigator
IRC
Group
Value
95% CI
TNBC
43.6
30.3 – 57.7
HR(+) /HER2(-) Breast Cancer
71.4
47.8 – 88.7
Investigator
Group
Value
95% CI
TNBC
41.8
28.7 – 55.9
HR(+) /HER2(-) Breast Cancer
66.7
43.0 – 85.4
Overall Survival (OS)Secondary· From the first dose of pamiparib until death (approximately 2 years and 10 months)
OS is defined as time from the first dose of pamiparib to the date of death due to any cause
Group
Value
95% CI
TNBC
17.08
15.57 – NA
HR(+) /HER2(-) Breast Cancer
27.89
18.10 – NA
Number of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)Secondary· Up to approximately 2 years and 10 months
A TEAE is defined as an adverse event (AE) that had an onset date on or after the first dose of study drug up to 30 days following study drug discontinuation. SAE is defined as any AE that leads to death or is life-threatening.
With At Least 1 TEAE
Group
Value
95% CI
TNBC
61
HR(+) / HER2(-) Breast Cancer
26
Grade 3 or higher
Group
Value
95% CI
TNBC
37
HR(+) / HER2(-) Breast Cancer
18
SAEs
Group
Value
95% CI
TNBC
12
HR(+) / HER2(-) Breast Cancer
7
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to approximately 2 years and 10 months.
Reporting threshold: 3%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
TNBC
Serious: 12/62 (19%)
Deaths: 31/62
HR(+)/HER2(-)
Serious: 7/26 (27%)
Deaths: 12/26
Serious adverse events (18 terms)
Reaction
System
TNBC
HR(+)/HER2(-)
Anaemia
Blood and lymphatic system disorders
—
—
Leukopenia
Blood and lymphatic system disorders
—
—
Febrile neutropenia
Blood and lymphatic system disorders
—
—
Neutropenia
Blood and lymphatic system disorders
—
—
Thrombocytopenia
Blood and lymphatic system disorders
—
—
Cataract
Eye disorders
—
—
Diarrhoea
Gastrointestinal disorders
—
—
Death
General disorders
—
—
Upper respiratory tract infection
Infections and infestations
—
—
Alanine aminotransferase increased
Investigations
—
—
Aspartate aminotransferase increased
Investigations
—
—
Platelet count decreased
Investigations
—
—
Spinal meningioma benign
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
—
—
Altered state of consciousness
Nervous system disorders
—
—
Cerebral haemorrhage
Nervous system disorders
—
—
Acute kidney injury
Renal and urinary disorders
—
—
Dyspnoea
Respiratory, thoracic and mediastinal disorders
—
—
Pleural effusion
Respiratory, thoracic and mediastinal disorders
—
—
Other adverse events (110 terms — click to expand)
This is a Phase 2, open-label, multi-center study of BGB-290 administered orally (PO) twice daily (BID) in adult Chinese patients with advanced HER2(-) breast cancer harboring germline BRCA mutation, which have progressed despite standard therapy, or for which no standard therapy exists.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for HER2-negative Breast Cancer
Currently open trials in the same condition.
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer
· recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
· Phase 2
· recruiting
NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin
· Phase 1, PHASE2
· recruiting
NCT06774027 — Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
· recruiting
NCT06970912 — ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
· Phase 2
· recruiting
Other BeiGene trials
Trials by the same sponsor.
NCT07169331 — A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglob
· Phase 4
· recruiting
NCT07100938 — A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheum
· Phase 2
· active not recruiting
NCT07005713 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-
· Phase 1
· active not recruiting
NCT06906809 — Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
· Phase 1
· completed
NCT06803680 — A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
· Phase 1
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BeiGene
Last refreshed: 26 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03575065.